Barrow Hanley Mewhinney & Strauss LLC Has $18.10 Million Position in Humana Inc. (NYSE:HUM)

Barrow Hanley Mewhinney & Strauss LLC trimmed its holdings in Humana Inc. (NYSE:HUM - Free Report) by 88.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,336 shares of the insurance provider's stock after selling 566,499 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned about 0.06% of Humana worth $18,099,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in HUM. Transcend Capital Advisors LLC raised its stake in shares of Humana by 399.7% during the fourth quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider's stock valued at $924,000 after purchasing an additional 2,914 shares in the last quarter. FNY Investment Advisers LLC raised its position in shares of Humana by 6,647.5% during the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider's stock worth $6,916,000 after buying an additional 26,856 shares in the last quarter. Retirement Systems of Alabama lifted its stake in shares of Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock worth $55,563,000 after acquiring an additional 192,801 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Humana by 7.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider's stock valued at $244,811,000 after acquiring an additional 65,735 shares in the last quarter. Finally, PDT Partners LLC boosted its holdings in shares of Humana by 190.0% in the third quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider's stock valued at $1,286,000 after acquiring an additional 2,660 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Remove Ads

Humana Stock Up 0.2 %

NYSE HUM traded up $0.46 on Wednesday, reaching $265.20. The stock had a trading volume of 1,117,200 shares, compared to its average volume of 1,753,515. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The business has a 50 day moving average price of $269.37 and a 200 day moving average price of $272.67. The company has a market capitalization of $32.01 billion, a price-to-earnings ratio of 26.65, a P/E/G ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.33%. Humana's dividend payout ratio (DPR) is presently 35.58%.

Analyst Ratings Changes

HUM has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut their target price on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research report on Tuesday, February 18th. Truist Financial upped their price objective on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a report on Monday, January 6th. Morgan Stanley lowered their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Barclays upped their price target on shares of Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Finally, Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. Eighteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.